RankAlpha logo
Back to Rankings

WAT

WatersA
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Bull case is that the BD Biosciences/Diagnostics acquisition starts to contribute meaningfully, Waters keeps outgrowing underlying end-markets, and raised FY26 guidance proves conservative; the Q1 print showed strong organic growth and better-than-expected owned-period revenue [#SEC-8K-2026-05-05].
Posture
Constructive
Lead driver
Momentum
What changed
5 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Acquisition integration and synergy timing could slip, especially because the first quarter still depended on commercial-execution and operational-improvement initiatives [#SEC-8K-2026-05-05].
Momentum
87
Value
60
Sentiment
57
Setup hits (3d)
5 · Net Bullish
AI TargetsBase $400.00 · Bull $440.00 · Bear $315.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-03 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Bullish
Target $401.25
Why
Momentum87 · Δ7d +27.5
Value60 · Δ7d -0.1
Sentiment57 · Δ7d -8.2
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
87
34% active weight
Current posture
7d trendImproving
Δ7d
+27.5
Δ21d
+44.5
Value
60
32% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+0.2
Sentiment
57
33% active weight
Current posture
7d trendSoftening
Δ7d
-8.2
Δ21d
-0.9
Why this grade

Composite grade A. Momentum 86.7 / Value 59.8 / Sentiment 57.2

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$37.13B
Beta
1.18
Shares Out
59.53M
P/E (TTM)
36.3
P/S (TTM)
7.57
P/FCF (TTM)
39.04
Rev YoY
+8.0%
EPS YoY
-8.0%
Gross Margin
+59.0%
Op Margin
+26.5%
Net Debt
$1.3B
Current Ratio
1.53
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology